{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=6",
    "query": {
      "intervention": "Placebo- C",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1833,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T14:09:57.702Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00698789",
      "title": "Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "INCB019602",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2012-10-30",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698789"
    },
    {
      "nct_id": "NCT03234738",
      "title": "A Phase 1 Safety and PK Study of IV TP-271",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TP-271",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetraphase Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-08-16",
      "completion_date": "2018-01-02",
      "has_results": false,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234738"
    },
    {
      "nct_id": "NCT02682225",
      "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Abuse"
      ],
      "interventions": [
        {
          "name": "Intravenous placebo",
          "type": "DRUG"
        },
        {
          "name": "Intranasal placebo",
          "type": "DRUG"
        },
        {
          "name": "Intravenous racemic ketamine",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 112 mg",
          "type": "DRUG"
        },
        {
          "name": "Esketamine 84 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 55,
      "start_date": "2016-03-25",
      "completion_date": "2017-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682225"
    },
    {
      "nct_id": "NCT01613040",
      "title": "A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "RO4917838 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 169,
      "start_date": "2009-01",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613040"
    },
    {
      "nct_id": "NCT07867340",
      "title": "A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "C-Reactive Protein"
      ],
      "interventions": [
        {
          "name": "LY5625573",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-09",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 2,
      "location_summary": "Los Alamitos, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07867340"
    },
    {
      "nct_id": "NCT02853435",
      "title": "To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "Gepotidacin RC Tablet",
          "type": "DRUG"
        },
        {
          "name": "Gepotidacin HSWG Tablet",
          "type": "DRUG"
        },
        {
          "name": "Gepotidacin Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-08-04",
      "completion_date": "2017-10-17",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Austin, Texas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02853435"
    },
    {
      "nct_id": "NCT00703573",
      "title": "A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "S-777469 400 mg",
          "type": "DRUG"
        },
        {
          "name": "S-777469 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 209,
      "start_date": "2008-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 33,
      "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703573"
    },
    {
      "nct_id": "NCT01582269",
      "title": "A Study in Recurrent Glioblastoma (GB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Galunisertib",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2012-04-26",
      "completion_date": "2024-10-10",
      "has_results": true,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582269"
    },
    {
      "nct_id": "NCT02915016",
      "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA-HIV-PT123 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/MF59 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/AS01B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 334,
      "start_date": "2016-12-07",
      "completion_date": "2020-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915016"
    },
    {
      "nct_id": "NCT00852969",
      "title": "Niacin and Endothelial Function in Early CKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Niacin",
          "type": "DRUG"
        },
        {
          "name": "Active Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-08",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-05-06",
      "last_synced_at": "2026-10-20T14:09:57.702Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00852969"
    }
  ]
}